News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new...
New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that new data show that the pivotal Phase 3 clinical SPARKLE study with the lead candidate drug Orviglance can be completed...
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic Impairment Study confirming that the company’s lead drug candidate, the magnetic resonance...
MinervaX announces that EMA has awarded PRIME Status for its Group B Streptococcal vaccine
MinervaX, a privately held Danish biotechnology company,today announces that EMA has awarded PRIME status for its vaccine against Group B Streptococcus (GBS).PRIME is aimed at enhancing support for the development of medicines that target an unmet medical need. This...
Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related...